演題詳細

一般口演 / Oral Session

一般口演 100 (Oral Session 100) :節外性B細胞リンパ腫

print

日程
2013年10月13日(日)
時間
15:00 - 16:00
会場
第8会場 / Room No.8 (ロイトン札幌 2F ハイネス)
座長・司会
正木 康史 (Yasufumi Masaki):1
1:金沢医科大学 血液免疫内科学
 
前へ戻る

M-protein is associated with aggressive disease in patients with extra nodal MALT lymphoma

演題番号 : OS-3-145

山内 寛彦 (Nobuhiko Yamauchi):1,3、数馬 安浩 (Yasuhiro Kazuma):1、長畑 洋佑 (Yosuke Nagahata):1、竹田 淳恵 (June Takeda):1、船山 由樹 (Yuki Funayama):1、小野 祐一郎 (Yuichiro Ono):1、田端 淑恵 (Toshie Tabata):1、米谷 昇 (Noboru Yonetani):1、松下 章子 (Akiko Matsushita):1、今井 幸弘 (Yukihiro Imai):2、石川 隆之 (Takayuki Ishikawa):1

1:Dept of Hematology, Kobe City General Hospital, Kobe, Japan、2:Department of Clinical Pathology, Kobe City General Hospital, Kobe, Japan、3:Foundation of Biomedical Research and Innovation, Kobe, Japan

 

MALT lymphoma is classified as an indolent lymphoma, but its clinical course is not uniform. The prognostic factor of MALT has not been well understood. This was a retrospective pooled analysis of pathologically confirmed MALT lymphoma patients in our institute. Patients with nodal or splenic marginal zone lymphoma were excluded. The primary endpoint was progression free survival (PFS). From January, 2001 to March, 2013, a total of 46 MALT lymphoma patients were referred to our institution, and included in this analysis. The median age of patients was 66 years (range 43-89), 36% had advanced stage MALT, and 89% had ECOG PS less than 2. 18% of patients had the malt1 mutation, 18% had M-protein. The numbers of patients who were diagnosed with orbital, thyroid, salivary gland, gastric, lung, intestinal MALT were 7(15%), 5(11%), 8(17%), 14(30%), 13(28%), 4(8%), respectively. After a median follow-up time of 50 months (range 1-142), 14 progression had occurred, and the 5 year PFS rate was 85.9%[95%CI, 71.3-93.4%]. Univariate analysis found M-protein, advanced stage, soluble IL-2 receptor value >700IU/L, lymphocyte count >1*10^9/l as a prognostic factor for PFS(p<0.05). In multivariate analysis including four variables mentioned above, only M-protein remained as a prognostic factor for PFS. The 5 year adjusted PFS for patients with M-protein was significantly inferior to that for patients without M-protein (34.3%[4.8-68.5%] vs 90.5%[73.1-96.9%]; HR,11.67; 95%CI,1.12-121.5; p=0.039). In conclusion, MALT patients with M-protein had an increased risk of early disease progression.

前へ戻る